Vyriad, Inc.
Vyriad, Inc.
Explore linked clinical trials.3 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1 Dose-escalation and Expansion Study of In Vivo BCMA-CAR T Cell Therapy (VV169) in Patients With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma Refractory; Multiple Myeloma in Relapse | Recruiting | Phase 1 | 2026-09-21 | NCT07802717 | |
| Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients | Digestive System Diseases, Digestive System Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, carcinoma, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, head and neck squamous cell carcinoma, intestinal disorder, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm, squamous cell carcinoma | Active, not recruiting | Phase 2 | 2026-07-08 | NCT04291105 | |
| Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, lung disorder, lung neoplasm, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, urinary system disorder | Active, not recruiting | Phase 1 / Phase 2 | 2025-09-16 | NCT03647163 |